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Aim: To investigate the adjuvant role of the antimutagenic agent chloroquine in the treatment of patients with malignant astrocytomas
(MAs).
Materials and methods: Clinical research was conducted at the Neurosurgery Clinic of the Erciyes University School of Medicine,
from September 2003 to April 2007, on 37 patients diagnosed with MA after tumor resection subsequent to craniotomy. Chloroquine
treatment was started on a daily dose of 150 mg, additional to the patients’ radiotherapy and chemotherapy protocol, and was continued
throughout the 43-month surveillance period. A control group was formed of 81 patients with MA after the craniotomy.
Results: While the mean survival time of the patients who were treated with chloroquine was found to be 15 months, during the
observation period 7 of these patients (18.9%) were alive throughout. In the control group, 20 patients (35.1%) were alive throughout
the observation period and their mean survival time was 17 months. There were no statistical differences between the control and
chloroquine groups (P > 0.05).
Conclusion: The chloroquine treatment was not been found to be effective for the medical treatment of MAs.
Key words: Chloroquine treatment, malignant astrocytomas, prognosis, antimutagenic effect

1. Introduction
In spite of improvements in anaplastic astrocytomas (AA)
and glioblastoma multiforme (GBM) diagnostic methods,
surgical techniques, and adjuvant treatment, the prognosis
of patients with malignant astrocytomas (MAs) is
unsatisfactory and is still being expressed in months (1,2).
Despite the use of radiotherapy (RT) and /or chemotherapy
(CT) as an adjuvant to surgical treatment with these
patients, eventual relapse is inevitable. It is known that in
these relapsing tumors, mutant clones resistant to RT and
CT can develop.
In this study, the adjuvant role of the antimutagenic
agent chloroquine, which has an optimum pharmacological
profile, in the treatment of MA patients was investigated.
The assumption that chloroquine, with its antimutagenic
features, added to standard treatment could prevent the
development of resistant mutant clones is the basis of this
study (3).
* Correspondence: mehmetali.ekici@gmail.com
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In the treatment of various parasitic and immunebased diseases, chloroquine has been used for the last 20
to 30 years. The mechanism of action in GBM treatment
is related to either the increase in cytotoxicity induced by
conventional treatment or the preservation of mutagenity
in neoplastic cells. In this study, the length and dose of
chloroquine treatment was planned based on clinical
experience obtained from the long-term treatment of
autoimmune diseases. The 150 mg/day dose used in studies
is accepted as a low dose (4). In addition, it is reported that
the dose can be increased up to 300 mg/day and still be
well tolerated (5).
2. Materials and methods
Clinical research was conducted at the Neurosurgery
Clinic of the Erciyes University School of Medicine, from
September 2003 to April 2007, on 37 patients diagnosed
with MA after tumor resection subsequent to craniotomy.
With demographic, neurological, radiological, surgical,
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and clinical features described prospectively and
assumed to affect prognosis, the effect of the addition to
adjuvant therapies of 150 mg/day oral chloroquine, an
antimutagenic agent, on the therapy and prognosis was
investigated in this clinical study.
Informed written consent was obtained from all the
patients in the treatment group, and in some cases from
their legal custodians. A total of 81 patients, as the control
group, diagnosed with MA based on tumor resection after
craniotomy and having the same treatment and followup criteria except for the chloroquine treatment, were
evaluated between November 1999 and August 2003.
2.1. Histopathologic diagnosis
Material obtained through surgical resection was examined
by an experienced neuropathologist and categorized as
astrocytomas of grades 3 and 4 (AA, GBM) according
to the classification of the World Health Organization
(WHO) (6). For this group, specially prepared tumor
follow-up forms for recording the radiological and clinical
features of the patients and treatment methods were
completed and kept. The patients’ ages, sex, and Karnofsky
performance score (KPSs) were recorded throughout the
study. Following the examination of their hospital records,
all the data related to CT and RT were recorded in their
respective forms. While asymptomatic patients were called
every 3 months, clinical and radiological data regarding
symptomatic cases were recorded on special tumor followup forms. At each application for control, a magnetic
resonance (MR) test was evaluated by an experienced
radiologist who was evaluating the patients for possible
relapse. Medicine toxicity was periodically followed up
through hematologic, renal, and hepatic function tests.
The families of those patients who failed to attend the
control sessions were contacted by telephone to determine
the neurologic and performance levels of the patients and
to invite them to periodic examinations. The death dates of
patients who died were obtained from their relatives. The
basic criterion for results was the patients’ life expectancy.
2.2. Imaging protocol
During the preoperative and postoperative period,
enhanced and unenhanced CT and MR imaging tests
of all patients were routinely performed. Tumor-related
features that were thought to be prognostic were identified

by an experienced radiologist. These features were tumor
density, localization, diameter, contrasting, extension to
opposite hemisphere, clarity of borders, and midline shift.
The distance of each tumor to the vital areas in the brain
was digitized using the grading system proposed by
Sawaya (7) (Table 1).
2.3 Surgical technique
Under general anesthesia, and after the Mayfield Headrest
and Skull Clamp System was applied, the position of the
patient was fixed using neuronavigation. To refine the
surgical deviation resulting from the brain shift throughout
the operation, a fusion of intraoperative ultrasound
images, with the navigation images adjusted by means of
the navigation system, was utilized, and this process was
repeated in real-time as required until the end of resection.
After resection, intraoperative ultrasound records were
obtained for residual tumors when necessary, and when
the resection was sufficient, hemostasis was started.
To diagnose any clinically overlooked surgical
complication, all the patients underwent CT in the first
4 h after the operation. To compare the degree of tumor
resection, and to determine the resection rate on the basis
of pre- and postoperative MR examinations, the areas
where the signal density increased in a high-contrasted T1
MR examination were accepted as tumor sites. These were
identified digitally through the 4/3 × r1 × r2 × r3 formula
and compared with preoperative enhanced T1 A MR
images. In the first postoperative 72 h, all the patients were
examined by MR and underwent gross total resection. MR
findings disagreed with the surgical findings.
2.4. Radiotherapy protocol
While conventional radiotherapy was planned for MA,
the surgeon’s opinion of the postoperative tumor volume,
surgical resection, and pre- and postoperative enhanced CT
and MR findings was considered. An effective irradiation
area was drawn on the medical mask on the simulator. In
the first part of the RT, with a LINAC teletherapy device
(Varian 2300 C, USA) at 6,000,000 eV, the area consistent
with the tumor, the edematic area around it, and the
2–3 cm brain tissue area outside were identified as the
target for the application of radiotherapy, and 40–50 Gy
radiotherapy was applied.

Table 1. Grading of malign astrocytomas according to functional location (7).
Grade

Location

I: Nonvital area

Frontal or temporal pole, parietooccipital lobe, cerebellar hemisphere.

II: Near vital area

Near; motor or sensory cortex, calcarine fissure, speech center, internal capsule, dentate nucleus, and brainstem.

III: Vital area

Motor or sensory cortex, visual and speech center, capsula interna, basal ganglia, thalamus, hypotalamus,
dentate nucleus, and brainstem.
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3. Results
3.1. Demographic features of the patients
Of the 37 patients in the chloroquine group, 22 were males
and 15 were females with a mean age of 50 years. In 3 of the
patients (8.1%), bleeding was detected through tomography
as a postoperative complication. In the chloroquine group,
relapse developed in 25 patients (80.6%), and 9 of these
patients were reoperated on. In the control group, 53 out
of 81 patients were male (65.4%), 28 were female (34.6%),
and 18 patients were reoperated on. The general features,
mean survival time (MST), and statistical differences of
the chloroquine and control groups can be seen in Table 2.
In the Figure, Kaplan–Meier life curves are shown for the
control and chloroquine groups.
3.2. Age and prognosis
The patients were divided into 3 age groups: those below
the age of 45 years, those 45–59 years old, and those 60
years old and above. In univariate analyses for the control
group, the mean survival time for patients in the group
below the age of 45 years was 19 months (CI 95%; range:
12–22), in the 45–59 years age group it was 12 months (CI
95%; range: 9–16), and in the group of age 60 and over
it was 6 months (CI 95%; range: 3–9). These findings in
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In the second part of the treatment, the target area was
narrowed a little, and the dose was increased to 60 Gy and
restricted to 60 Gy in 30 fractions over 6 weeks, the level
tolerated by the central nervous system,
2.5. Chemotherapy protocol
After pathological diagnosis, 60 Gy in 30 fractions over
6 weeks was administered. With the first dose of RT, 37
patients were given 75 mg/m2 of daily oral temozolomide,
and the same dose was continued for the 6-week course of
RT. After RT, 200 mg/m2 of 1–5 days of oral temozolomide
was given at 4-week intervals, and 6 cycles were
completed. The performance scores and hematological,
renal, and hepatic functions of the patients were followed
closely to make sure they were at normal levels. In cases
where aberrant values were found, the CT protocol was
interrupted until the values reached normal levels.
2.6. Statistical method
After the operation date, the cumulative lifetimes of
the patients were calculated through the Kaplan–Meier
method. The survival curve of various inferior groups
was compared through the log-rank test. The effect of the
multivariables related to patients’ survival was analyzed
through the Cox regression method. In this study, raw
and processed data were calculated within a confidence
interval (CI) of 95%. Statistical analyses were performed
with the SPSS 10.0 (SPSS Inc., Chicago, IL, USA).
Statistical significance was defined at P < 0.05 and P < 0.01.
A statistically insignificant value was defined as P > 0.05.
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Figure. Kaplan–Meier life curves of the control and chloroquine
groups.

the patient group below 45 years old as compared to those
in the group of patients age 60 and over were statistically
significant (P < 0.01), and the younger patients had
longer survival times. Compared with the patient group
of 60 years and above, the age group of 45–59 years had
statistically more significant and longer survival times
than those in the group of 60 years and above (P < 0.05). In
univariate analyses for the chloroquine treatment group,
the mean survival time for patients in the group below the
age of 45 years was 18 months (CI 95%; range: 13–23), in
the age group of 45–59 years it was 15 months (CI 95%;
range: 12–19), and in the age group of 60 years and older
it was 7 months (CI 95%; range: 4–11). These findings in
the patient group of below 45 years and those in the age
group of 60 years and older were statistically significant
(P < 0.05). Patients 45 years old and younger had longer
survival times compared with those 60 or older. The age
group of 45–59 years had statistically more significant and
longer survival times than those in the group of patients of
60 years and older (P < 0.05).
The MST of the patients according to their age groups
is presented in Table 2. While the younger age groups
had statistically significantly longer life expectancy, the
differences in survival times and rates in the chloroquine
and control groups were found to be statistically
insignificant in terms of the prognosis of the disease (P >
0.05; Table 2).
3.3. Localization of the tumor and relapse time
In the chloroquine group, 20 tumors were localized in the
vital area, 10 in the nonvital area, and in 7 cases near the
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Table 2. Demographic and characteristics of patients in the chloroquine and control groups.
Chloroquine group
Variable

n = 37

Mean age (range), years

50 (27–72)

Localization

Preoperative Karnofsky score

P
(between the
groups)

50 (21–76)
18 (13–23)*

33

19 (15–22)ƦƦ

P > 0.05 Ώ

11

15 (12–19)*

26

12 (9–16)Ʀ

P > 0.05 Ώ

10

7 (4–11)

22

6 (3–9)

P > 0.05 Ώ

Male (%)

22 (59.5)

15 (11–19)

53 (65.4)

13 (10–15)

P > 0.05 Ώ

Female (%)

15 (40.5)

13 (9–16)

28 (34.6)

14 (10–19)

P > 0.05 Ώ

Nonvital area

10

16 (9–22)

11 (13.6)

17 (9–25)

P > 0.05 Ώ

Near vital

7

15 (8–22)

22 (27.2)

14 (10–19)

P > 0.05 Ώ

Vital area

20

13 (10–16)

48 (59.3)

12 (9–14)

P > 0.05 Ώ

<70

2

11 (3–18)

27

9 (5–12)

P > 0.05 Ώ

≥70

35

15 (12–18)

54

16 (13–18)ƦƦ

P > 0.05

≥60
Sex

n = 81

Mean survival
time (CI 95%)

16

<45
45–59

Age group

Mean survival
time (CI 95%)

Control group

Operation with neuronavigation

34 (91.9)

Gross total resection (>95%)

31 (83.8)

16 (13–20)**

42 (51.9)

17 (13–20) ƦƦ

P > 0.05 Ώ

Subtotal resection

6 (16.2)

6 (2–10)

39 (48.1)

10 (8–13)

P > 0.05 Ώ

<70

2

11 (3–18)

35

7 (4–10)

P > 0.05 Ώ

≥70

35

15 (12–18)

46

18 (5–21)ƦƦ

P > 0.05 Ώ

GBM

32 (86.5)

15 (11–19)

66 (81.5)

12 (9–14)

P > 0.05 Ώ

AA

5 (13.5)

13 (9–17)

15 (18.5)

20 (14–26)ƦƦ

P > 0.05 Ώ

37 (100)

15 (11–18)

81

17 (15–20)

P > 0.05 Ώ

9

17 (13–21)

18

18 (15–22)

P > 0.05 Ώ

(<95%)

Postoperative Karnofsky score
Histopathology
Radiochemotherapy
Reoperation

67 (82.7)

*: P < 0.05 in the chloroquine group, <45 age group versus ≥60 age group and 45–59 age group versus
≥60 age group.
**: P < 0.01 in the chloroquine group, gross total resection versus subtotal resection.
Ώ: P > 0.05 between the groups, chloroquine subgroups versus control subgroups
ƦƦ: P < 0.01 in the control group, <45 age group versus ≥60 age group pre- and postoperative Karnofsky
score of <70 versus ≥70 and gross total resection versus subtotal resection, and AA versus GBM.
Ʀ: P < 0.05, age group 45-59 versus ≥60 age group in the control group.

vital area. In the control group, 48 tumors were in the vital
area, 11 in nonvital area, and in 22 cases near the vital area.
In inter- and intragroup comparisons of the chloroquine
and control groups, tumor localizations in relationship to
the vital areas were found to be statistically insignificant in
terms of survival times and rates (P > 0.05; Tables 2 and 3).
In the chloroquine group, the mean relapse time of the
tumor cases localized in the nonvital area was 11 months.
The mean relapse time in the case of tumors localized in
the vital area was 14 months, and for those localized near
the vital area, it was 12 months. The relationship between
tumor localizations and relapse times was found to be
statistically insignificant (P > 0.05).

In the control group, the mean relapse times for tumors
localized in the nonvital area and in the vital area were
11 and 7 months, respectively, while it was 9 months for
those near the vital area. The relationship between tumor
localization and relapse time was found to be statistically
insignificant in the chloroquine and control groups (P >
0.05; Table 3).
3.4. Preoperative and postoperative KPS scores
In the chloroquine group, the patients with a KPS of >70
had a longer life expectancy compared to those with a KPS
of <70, the difference between the groups being statistically
insignificant (P > 0.05).
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Table 3. Relapse time and related factors in gross total resection groups.
Chloroquine group
Variable

Control group

n = 31

Survival
rate %

Mean relapse time
(CI 95%)

n = 42

Survival
rate %

Mean relapse time
(CI 95%)

GBM

20

15.0

13 (9–17)

33

36.4

6 (4–7)*

AA

5

0

9 (5–14)

9

66.7

15 (11–19)*

I

6

16.7

11 (8–14)

7

57.4

11 (5–17)*

II

9

11.1

12(8–16)

17

41.2

9 (5–13)*

III

10

10.0

14 (8–20)

18

38.9

7 (4–11)*

Radiochemotherapy

31

18.9

12 (9–16)

42

54.8

11 (9–14)*

Gross total resection (relapse)

25

12.0

12 (9–16)

28

53.6

9 (6–11)*

Histopathology

Localization

*: P > 0.05 between the subgroups related with effect on relapse time. Chloroquine subgroups versus control subgroups.
In the chloroquine group, 31 patients had gross total resection rate. In the control group, 42 patients had gross total resection rate.
Relapse time and related factors were analyzed in each group. It was detected that there were no statistically significant differences
between the subgroups that affected relapse time.

In the control group, the difference between the patients
with KPS > 70 and KPS < 70 was statistically significant (P
< 0.01) in terms of MST. When the preoperative KPSs of
the patients in the chloroquine and control groups were
compared in terms of the disease, differences in survival
times and rates were found to be statistically insignificant
(P > 0.05). There was no statistically significant difference
of MST and median survival times between the patient
groups with KPS > 70 and KPS < 70 in the chloroquine
group (P > 0.05). When the postoperative KPSs of the
patients in the chloroquine and control groups were
compared, statistically significant differences of survival
time and MST were detected in the control group (P <
0.01). When the chloroquine and control groups were
compared in terms of the prognosis of the disease,
differences in their KPSs and survival times and rates were
found to be statistically insignificant (P > 0.05; Table 2).
3.5. Resection level
In the chloroquine group, 34 patients were operated on with
the accompaniment of neuronavigation, and 31 patients
were determined, based on the postoperative MRI, to
have gross total resection. In the control group, 67 patients
were operated on with neuronavigation, and their early
postoperative MRI recordings revealed that 42 patients
(51.9%) underwent total resection and 39 (38.1%) patients
underwent subtotal resection. In the control group, relapse
developed in 28 (66.7%) patients, and 18 (22.2%) of those
were reoperated on (Table 2). In the chloroquine group,
when the relapse times of the total resection group and
regrowth of the subtotal resection group were analyzed,
the mean relapse time was 12 months in the total resection
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group. In the subtotal resection group, the mean regrowth
time was 3 months. The difference between the groups was
statistically significant (P < 0.05). In the control group,
while the average relapse time was 9 months in the total
resection group, the mean regrowth time was 5 months
in the subtotal resection group. There was a statistically
significant difference between the gross total and subtotal
groups (P < 0.05). In terms of the prognosis of the disease,
the rates and levels of the resection and the relapse times
in the chloroquine and control groups were statistically
insignificant (P > 0.05) (Tables 2 and 3).
3.6. Radiotherapy–chemotherapy and relapse time
In the chloroquine group, 25 of the patients receiving
RT and CT were detected to have relapse, and 3 of these
patients (12.0%) were alive during the follow-up, their
mean relapse time being 12 months. In the control group,
the mean relapse time was determined at 11 months in
RT- and CT-receiving patients. In the chloroquine and the
control groups, in terms of the prognosis of the disease,
the relationship between RT and CT and relapse time was
found to be statistically insignificant (P > 0.05; Table 2).
3.7. Pathological diagnosis and relapse time
The histopathological diagnoses and the relapse times
of the patients treated with chloroquine were examined.
In the chloroquine group, the mean relapse time of the
patients with AA was determined at 9 months, while it
was 13 months for the patients with GBM. The difference
between the histopathological subgroups was found to
be statistically insignificant (P > 0.05). Table 3 presents
Kaplan–Meier survival curve information of the patients
in the chloroquine group based on their pathological
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diagnosis and the relapse time. In the control group,
the mean relapse time of the patients with AA was 15
months, but for those with GBM it was determined at 6
months. The difference between the relapse times of the
histopathological subgroups was found to be statistically
significant (P < 0.01).
The pathological diagnosis and the relapse time rates
in the chloroquine and the control groups were found
to be statistically insignificant (P > 0.05) in terms of the
prognosis of the disease (Table 3).
4. Discussion
The prognosis of GBM patients has changed little in
the last decade. The most recent studies show that after
an aggressive treatment consisting of a combination of
surgical therapy, radiotherapy, and chemotherapy, the
average life expectancy of the patients is about 1 year (1).
Chloroquine firmly binds to nucleic acids, especially to
DNA’s cytosine–guanine sequence. It tonifies the structural
configuration of DNA and prevents mutagenesis.
Chloroquine leads to stabilization of the p53 protein and
induces the p53 transcriptional target in glioma cell lines
with wtp53. The p53 independent cytotoxic effects of
chloroquine are well known and are related to the ability
of chloroquine to cause mitochondrial dysfunction as a
result of the inhibition of lysosomal autophagy (2).
This effect has been shown in many eukaryotic cells,
including viruses, bacteria, and various cancer cells (8,9).
Apart from this important feature, chloroquine, a necrosis
factor, acts almost like an immunomodulatory by inhibiting
phospholipase A2 and tumors (10). Furthermore, it
impairs the DNA cell repair mechanism that results from
the degradation induced by alkylating treatment (11).
In vitro, chloroquine blocks the antigenic protein
expression on the surface of malignant glial cells and
penetrates these cells. Because of its reducing effect on
the DNA’s cell repair mechanism and DNA synthesis,
chloroquine strongly reveals the inhibitive effect of
radiation on cell proliferation. Although chloroquine
alone is a cytotoxic, when accompanied by ionizing
radiation, it causes subsequent changes in cell structure
such as carcinoma and melanoma, as well as serious
ultrastructural lesions characterized by microtubule
and microfilament increase, mitochondrial damage, and
endoplasmic reticular vacuolization (12).
Furthermore, other intracellular effects of chloroquine
can increase the irritability of malignant glioma cells to the
standard treatment. Because of the elevation of endozoic
and lysosomal pH, which increases and sustains the
concentration of the lipophilic antineoplastic drugs like
carmustine, it increases the permanence of cancer cells
(13).

The remarkable effect of chloroquine, which somehow
effectively reverses the multidrug resistance of cancer cells,
is that it delays or prevents the extracellular transportation
of anticancer medications like vincristine (13). Finally,
the addition of chloroquine to leukemic cell cultures with
multidrug resistance has been able to reduce the resistance
to vinblastine by between 10- and 15-fold (13,14).
Malignant cell clones that are resistant to CT and RT
cause treatment failure in GBM patients. It is because of
this resistance that the addition of new treatments to the
conventional treatment is thought to improve results (15).
High mutagenesis in malignant cells is a primary
factor in determining whether cell clones are resistant
to chemotherapy. Quinacrine binds firmly to DNA,
preventing mutagenesis. In a study on rats, Reyes et al. (16)
reported that quinacrine added to carmustine treatment
increased the antineoplastic effect of carmustine and
prolonged its effectiveness. According to their conclusions,
the inhibition of mutagenesis in malignant glial cells
during chemotherapy prevents the emergence of resistant
clones.
Because of all these effects, chloroquine has been
thought to contribute to recovery in GBM treatment.
Briceno et al. (17,18) reported that chloroquine, which
has an antimutagenic profile, considerably increases MA
response to antineoplastic therapy. This finding has been
ascribed to the antimutagenic effect, which prevents the
emergence of resistant clones during RT and CT.
Briceno et al. (17,18) also noted that chloroquine
treatment affects the patients’ MST and relapse time
positively. In our study, however, the difference
between the chloroquine and control groups was not
statistically significant (P > 0.05). In inter- and intragroup
comparisons, the pathological diagnosis and relapse time
rates were found to be statistically insignificant in terms of
the prognosis of the disease (P > 0.05). Our findings do not
support those of Briceno et al. (17,18).
There is little information about the effects of the age
factor in MA on radiosensitivity. Kumabe et al. (19) found
that 22 patients with malignant glioma and complete
reaction to RT were younger than those with less reaction.
In another study (20), the mean age of 11 GBM patients
who showed complete reaction to the radiation was 42.
Even this age is younger than that of GBM patients in most
studies (21).
Barker et al. (22) detected that, along with variables
such as extended surgical resection and high preoperative
KPS, the younger age of the patient also enhances the
response to radiation. There is important evidence that
shows a relationship between the age and longer life
expectancy in adult patients with MA. Mortality risk
increases with age. Aggressive treatment is less effective
in older patients than in younger patients in terms of
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prolonging life expectancy (22). In the present study,
statistically significant differences of survival were found
in the chloroquine group between the patients aged below
45 years and the age group of 45–59 years (P < 0.05). In the
control group, however, a statistically significant longer life
expectancy was detected in the patients aged below 45 and
in those in the age group of 45–59 years (P < 0.01 and P <
0.05, respectively). In terms of the prognosis of the disease,
an intergroup comparison of the survival times and rates
did not show any statistical difference (P > 0.05). These
findings in the control and study groups are consistent
with the literature data.
The 2 clinical variables that determine the radiation
reaction in MA patients are the KPSs of the patients before
RT and the degree of surgical resection (22). Curran et al.
(23) argued that MA patients with superior performance
and more comprehensive resections responded to RT
more favorably. It has been reported that high tumor
metabolism can be detected through positron emission
tomography screening of the MA patients with low KPSs
(24).
In some studies on the effect of surgery on life
expectancy, the findings have been in favor of aggressive
tumor resection (22,25).
In this study, inter- and intragroup comparisons of the
effect on MST of the tumor localization in relationship
to the vital areas were also performed. Although MST
was detected to be longer in cases of tumors in nonvital
areas, this finding was statistically insignificant (P > 0.05).
However, the findings are of a nature to corroborate the
findings from previous studies.
The effect of surgery on immunotherapy can emerge
through the reduction of tumor load and a mechanical
disorder in the blood–brain barrier (26). In numerical
studies on tumor size in patients with recurrent MA, it has
been noted that when the postoperative size of the tumor
is small, survival is significantly longer (27). Theoretical
tumor models indicate that smaller-sized tumors can show
greater radiosensitivity (28).
Salcman (29) defended the validation of comprehensive
surgery based on the literature screening of selected
patients who did not have adjuvant therapy, even if he did
not allow for tumor localization in his analyses.
In the literature (22,25), along with the studies that
indicate that the bigger the resection is, the longer the
lifetime will be, there are also some studies that show
that the degree of resection has no effect on survival rates
(30). On the other hand, Iliadis et al. (30) reported that
net-enhancing tumor volume before radiochemotherapy
was a statistically significant independent variable in the
multivariate Cox analysis. However, in the studies on
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general prognostic factors, the extent of resection is the
more often observed factor that has a desirable effect on
survival time (22,25).
In this study, a statistically meaningful difference
between the chloroquine group and the control group
was not determined when considering MST (P > 0.05).
However, in intragroup comparisons, the total resection
patients in both the control and treatment groups had
longer lifetimes compared to those in the subtotal
resection group. In terms of the prognosis of the disease,
the degree of resection and the regrowth time were found
to be statistically significant in intragroup comparison
(P < 0.05), but not in intergroup comparisons (P > 0.05).
Even though these findings support the literature findings
that aggressive surgical resection improves the prognosis,
it shows that chloroquine treatment does not have a
favorable effect on regrowth.
Curran et al. (23) found that radiation reaction was
assessed as better in terms of image in MA patients, with
better performance and more comprehensive resections.
In this study, survival times and rates were found
statistically insignificant in patients with RT in intergroup
comparisons (P > 0.05). This finding is far from supporting
the thesis and main idea of this study, that chloroquine
treatment could be effective in maintaining the irritability
of tumor cells to RT.
Sotelo et al. (5) reported that survival advantage could
be achieved in the medium term in the chloroquine and
control groups, but the long-term prognosis is poor.
Our findings do not support the findings of Reyes (16)
and Briceno et al. (17,18), and chloroquine treatment has
not been found effective in increasing sensitization to RT
and CT.
The addition of adjuvant treatments, such as CT and RT,
to the surgical treatment of GBM can increase patients’ life
expectancy in the medium term. However, the long-term
prognosis is still far from satisfactory. The data regarding
chloroquine, with its antimutagenic feature that has
been established in laboratories and also the remarkable
improvement it provides in the prognosis of the patients
through clinical usage, have been the basis for the planning
stage of this study. However, the results we obtained do not
support the previous studies on this subject, and they are
disappointing in terms of the prognosis.
Finally, contrary to previous studies, chloroquine
has not been found to increase the response of GBM to
antineoplastic treatment. Our findings do not support the
findings of the previous studies, and chloroquine has not
been found effective for the medical treatment of highgrade astrocytomas. Further studies on larger patient
groups, with dose comparisons, could clarify the subject.
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